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ABSTRACT
The Ras superfamily of G-proteins are of great research interest for structure-function
relationships among proteins as they act as molecular switches in the regulation of various
biochemical reactions in the cell. They are regulated by protein-protein interactions targeted to
the highly flexible switch regions. Mutations in G-proteins or their effectors may cause
alterations in structure and/or function that can lead to overactivity.
The Ras-related protein Cell division cycle 42 (Cdc42) is important in regulating cellsignaling processes. The T35A mutation in Cdc42 leads to a decrease in flexibility of the Switch
I region responsible for effector binding 3. The kinetics of the intrinsic GTP hydrolysis reaction
were compared for Cdc42 (WT and T35A) in the absence and presence of a peptide derivative of
PAK21 activated kinase (PBD46). The mutation does not affect the intrinsic GTP hydrolysis rate
of Cdc42, but binding with PBD46 is altered by the mutation; in the presence of PBD46, GTP
hydrolysis is completely inhibited for Cdc42 WT while partial recovery of GTP hydrolysis for
Cdc42 T35A was observed in the presence of PBD46. The data obtained lead us to propose two
slowly interconverting conformational states of Cdc42 T35A, both able to hydrolyze GTP, but
one that shows a weakened affinity for PBD46.
Ras homolog enriched in brain (Rheb) is a member of the Ras superfamily of proteins
known to regulate cell growth and proliferation by signaling the mammalian target of rapamycin
(mTOR) pathway. The Tuberous Sclerosis Complex 2 protein (TSC2) regulates Rheb by
functioning as a GTPase activating protein (GAP). At present, very little is known about the
molecular features of the Rheb-TSC2 protein interaction. We present biochemical and
biophysical data on the interaction of Rheb with TSC2 WT, using a shorter, 218 amino acid
GTPase derivative of TSC2 (TSC2-218), as well as with the mutant TSC2-218 K114A, to

characterize the TSC2-218 constructs and their GAP activity towards Rheb. A decrease in
secondary structure as well as a loss of GAP activity is seen in the K114A mutant compared to
WT.
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CHAPTER 1: INTRODUCTION

1.1 RAS
Structure-function relationships among proteins are crucial for evaluating the biological
processes associated with these proteins. Understanding the chemical and biological aspects of
these interactions can give much insight into how therapeutic treatments may be developed to
combat diseased-states such as cancer. The Ras superfamily of G-proteins are of significant
research interest as they act as molecular switches in the regulation of various biochemical
reactions in the cell and are controlled via cycling between nucleotide-bound states4. Their cell
signaling activity is dictated by the bound nucleotide; a biologically active GTP-bound form and
an inactive GDP-bound form.
Ras proteins have been highly conserved through eukaryotic evolution 5. Three ras genes
have been identified in mammals, H-ras-1, K-ras-2, and N-ras, and are known as p21 6-8. All
known Ras proteins contain 85 identical amino acids at the amino terminus. The subsequent 80
amino acids vary within the different proteins, although there is 85% homology between any pair
of Ras proteins. The last domain exhibits the most variation among Ras proteins, although the
carboxyl terminus always ends in C-A-A-X-COOH, where A is any aliphatic amino acid; this is
important so that the protein can be targeted to the periphery of the cell membrane after it has
been biosynthesized by lipidation 9.
Although comprised of multiple subfamilies with varying functions in the cell, Ras
GTPases share similar structure in a G domain, the GTP/GDP binding domain 10. This G domain
includes the switch I, switch II and P loop regions (phosphoryl binding loop) 11. Residues 25-40
1

make up the switch I region and residues 57-75 make up the switch II region responsible for
hydrophobic, polar, and charged interactions with the effectors 12-15. Ras contains a highly
conserved glycine (G12) in the P-loop 11, 16. The nucleotide binding region exhibited in Ras
GTP-binding proteins is highly conserved 17. The phosphate groups of the nucleotide interact at
the P loop, with a general sequence 10GXXXXG15, as well as residues 116-119 with a sequence
116

NKXD119 18, 19. Mutation of the glycine at position 12 to anything other than proline leads to

inherent activation 20-22, which can also occur if this residue is deleted or if insertions occur
immediately before 23. Changes in this residue disrupt the α-helical structure lead to improper
folding 24-26. If the subsequent glycine (G13) is mutated to either valine or aspartic acid,
oncogenic activity is induced in the protein 27. Ras also contains a conserved glutamine residue
(Q61) in the nucleotide binding domain that stabilizes the nucleotide and is, therefore, important
for GTP hydrolysis 28-30. This residue is the most

GAPs

frequently mutated residue in human cancers;
replacement of leucine for this glycine increases the GTP
bound levels by causing resistance to Ras GAP activity
31

GTP-bound
Active State

GDP-bound
Inactive State

. The cycling between the GTP- and GDP-bound states

of Ras GTPases is a result of the high affinity of the G
domain for these nucleotides 32 and is catalyzed by
regulatory proteins (Figure 1). The GTP-GDP exchange
is stimulated by guanine nucleotide exchange factors

GEFs
Figure 1. G-protein GTP/GDP
cycle. GAPs and GEFs regulate
the active and inactive states.

(GEFs), which interact at the switch I and switch II regions. Upon binding to GTP, a
conformational change is induced in Ras that favors protein-effector interactions that facilitate
activity 33. GTPase-activating proteins (GAPs) stimulate GTP hydrolysis; hydrolysis causes a
2

conformational change that lowers the protein’s affinity for effectors, thereby causing
inactivation. Ras GAPs work to stabilize the conserved switch II glutamine responsible for
stabilization of the hydrolytic water responsible for hydrolysis of the γ-phosphate through the use
of an arginine residue that forms hydrogen bonds with a bridge oxygen atom of GTP 31, 34, 35.
Guanine dissociation inhibitors (GDIs) stabilize the GDP-bound form of GTPases and prevent
membrane localization 36. Abnormal expression, often as a result of various mutations, in
GTPases is responsible for a large proportion of cancer types. Mutations often lead to a loss of
GTPase activity which prolongs the GTP-bound conformation and keeps the GTPase in an
uninterrupted active state; extended overactivity often results in cancer 9, 37. Abnormal
expression in Ras proteins have been implicated in up to 30% of human cancers 37. For these
reasons, the GTPases are hopeful drug targets for anticancer therapy.
1.2 CDc42
Cdc42 is a member of the rho subfamily of the Ras superfamily of GTPases, which plays
significant roles in the regulation of cell proliferation and differentiation by binding to effectors;
upon effector binding, a cascade of kinase interactions is activated. P21-activated kinase, a
serine/threonine kinase, is one such kinase 38. Like other Ras proteins, Cdc42 has the potential to
signal overactivity if its active state is not regulated as GTP concentration in the cell is much
higher than that for GDP 38. A 46-amino acid peptide derived from PAK (PBD46) interacts with
Cdc42 with high affinity 38, 39 and prevents GTP hydrolysis by stabilizing Cdc42 in the GTPbound state with a slow exchange rate 38. This interaction, which occurs in the highly flexible
switch I and switch II regions 33, 38, initiates a signaling cascade leading to the activation of
multiple kinases 40. PBD46 was derived from PAK1, one of the four subtypes of PAK, and
NMR structures have revealed that, while unstructured in its free form, PBD46 undergoes a
3

conformational change upon binding to Cdc42 41. This conformational change is partnered with a
decrease in flexibility exhibited in Cdc42 upon interaction 38.
Structural studies on Cdc42 have identified 6 β-sheets, 5 α-helices and 10 loop regions 42.
NMR solution studies have shown that PBD46 interacts primarily with a β-strand (β2) via an
antiparallel intermolecular extension, as well as with portions of α1, α5, switch I, and switch II 38,
39, 41

. Further NMR studies by Gizachew, et al. implied that the Cdc42-PBD46 interaction is

stabilized by hydrophobic interactions and that the strong binding energy can be attributed to the
interaction between the carboxylate group of glutamic acid at position 15 in PBD46 and the
hydroxyl group of tyrosine at position 40 in Cdc42.
The switch I and switch II regions are both highly flexible regions responsible for
effector interaction. Single point mutations involving various residues in the Switch I region
have an effect on the effector binding of Ras proteins 43. The phenylalanine at position 28 is
important as its aromatic ring stabilizes the nucleotide 82-84. Mutation of phenylalanine to leucine
at this position in Cdc42 (Cdc42 F28L) is referred to as a fast cycling mutant; it is characterized
by an increased exchange rate between GTP and GDP 85. This rapid exchange can be attributed
to an increase in flexibility in the nucleotide binding site that lowers the affinity for the
nucleotide 85; specifically, NMR studies indicated that the F28L mutation altered the binding site
around the α and β phosphate groups of the nucleotide, but no modifications were seen around
the γ phosphate 17, 86. Also in the Switch I region of Cdc42, as with other Ras proteins, an
invariant threonine at position 35 is critical for function. Preliminary observation of a threonine
to alanine point mutation at this residue (Cdc42 T35A) shows that, although the thermal stability
is not effected, less effector binding occurs and this weakened interaction may be a result of the
4

loss of conformational freedom in the Switch I region, supported by solution structure backbone
dynamics studies and biochemical characterization, due to the removal of the hydroxyl side chain
of residue 35 3, 44. Our hypothesis is that the weakened binding between Cdc42 T35A and
PBD46 could restore the GTP hydrolysis activity characteristic of Cdc42. We use a GTP
hydrolysis assay to compare the intrinsic GTP hydrolytic activity of Cdc42 T35A to Cdc42 WT
in the absence and presence of PBD46. The results show that both Cdc42 T35A and Cdc42 WT,
in the absence of PBD46, demonstrate similar hydrolytic efficiency. However, Cdc42 T35A still
exhibits a fraction of GTP hydrolysis in the presence of PBD46 in contrast to the complete
inhibition observed for WT. The data suggest that there may be multiple slowly interconverting
conformations of Cdc42 T35A that may have different or weakened interactions with PBD46.
This study highlights the potential for development of a way to restrict flexibility as a means to
control oncogenic protein-protein interactions.
1.3 RHEB
Rheb (Ras homology enriched in brain) proteins belong to the Ras superfamily of Gproteins 21, 45. Due to the cycling between GDP and GTP, as with other Ras proteins, Rheb must
be regulated through protein-protein interactions. Upon binding to GTP, a conformational
change from the GDP-bound form is induced, which allows Rheb to regulate cell growth through
its role in signaling through the insulin/TOR/S6K pathway 46-50. Overall sequence similarity is
seen between Rheb and Ras, with a few key differences 49. Rheb contains an arginine (R15) at
the position equivalent to the conserved glycine (G12) in Ras 20-22. Substitution of glycine for
arginine at position 15 in Rheb does not restore hydrolytic activity as would be expected for its
equivalence in Ras51. In Rheb, mutation of the homologous glutamine residue to leucine (Q64L)
does not inhibit protein-protein interactions; this residue is catalytically useless, due to its buried
5

orientation in a hydrophobic pocket, and does not participate in GTP hydrolysis 1, 45, 52. Due to
these differences, Rheb has an intrinsically low rate of GTP hydrolysis and, as such, must be
regulated by protein-protein interactions in order to prevent overactivity by remaining in the
GTP-bound active state 20, 53, 54. Therefore, outlining the correlation between structure and
function is crucial for understanding, at the molecular level, what underlies the onset of the
diseased-state.
The genes of the tuberous sclerosis complex, TSC1 and TSC2, were first identified as
tumor suppressor genes 55. The TSC1 gene encodes for the protein TSC1 (hamartin), which has
a “coiled-coil” domain near its carboxy terminus; this domain binds with high specificity to a
domain found at the amino terminus of TSC2 (tuberin) 54, 56. TSC1 and TSC2 interact to form a
heterodimer called the tuberous sclerosis complex (TSC). The TSC1 and TSC2 proteins share
limited homology with any other proteins 57 with the exception of the C-terminus of TSC2 which
contains a highly conserved domain that is homologous to Rap1GAP 55, 58. It was suggested that
the GAP domain of TSC2 interacts directly with a GTPase in order to facilitate the tumorsuppressing function of the complex 54, 55, 59. Rheb was determined to be a direct target for TSC
GAP activity 45-47, 52, 55, 60. The TSC1/TSC2 complex functions as a Rheb GAP; an interaction
between Rheb and TSC2 mediates the mTOR pathway and therefore regulates cell growth and
energy and nutrient levels (Figure 2). An extensive search of the literature does not reveal the
specific role of TSC1 in the Rheb/TSC2 interaction 46, 50, 53, 55, 61, 62, only that it is required for the
stabilization of TSC2 against ubiquitination 63, 64. As a GAP, TSC2 stimulates GTP hydrolysis
in Rheb through what has been suggested to be a catalytic “asparagine thumb” based on the
homology to Rap1GAP, which also functions via the “asparagine thumb” 65-67. TSC2 differs
from its interaction in Rheb from other Ras GTPases and their GAPs in the presence of this
6

“asparagine thumb” as mentioned. This interaction differs in that it is not characterized by the
“arginine finger” motif present in the activation of other GTPases like Ras 34. Incorporation of
an arginine residue in place of the asparagine residue that resulted in complete loss of GAP
function proved that TSC2 could not function via a RasGAP-like “arginine finger” mechanism
45

. Therefore, it is necessary to outline the molecular features of the Rheb-TSC2 protein-protein

interaction that are important in the regulation of cell-signaling pathways dictated by this
interaction.
A truncated version of TSC2 containing the GAP domain (TSC2-218) has been shown to
interact with Rheb in vitro 45. Mutations in the GAP domain of TSC2 have been described as
leading to the onset of tuberous sclerosis, a genetic disorder associated with benign tumors called
hamartomas that are often accompanied by the onset of seizures and mental retardation, due to
the function of the GAP domain to increase intrinsic Rheb GTP hydrolysis activity; when
mutated, the GAP activity of TSC2 towards Rheb is altered 46, 53-55, 68-70 (Figure 3B). The
underlying biological mechanism by which TSC2 catalyzes GTP hydrolysis is not yet completely
understood, but examination of disease-associated GAP domain mutants of TSC2 can allow for
the study of the molecular mechanism of TSC2 GAP activity. Our hypothesis is that mutations
in TSC2 are either unable to bind to Rheb, and therefore unable to function as GAPs, or they
bind, but are unable to catalyze GTP hydrolysis.
Through the use of several biochemical and biophysical techniques including circular
dichroism and differential scanning calorimetry, it is apparent that the K114A mutation in TSC2218 leads to a change in secondary structure and thermal stability; these structural differences,
compared to WT, could explain the loss GAP activity towards Rheb seen in the kinetics studies
and the lack of binding seen in the binding assays. Where TSC2-218 WT functions to stimulate
7

Rheb GTP hydrolysis, a very low rate, similar to that of Rheb, was seen for Rheb in the presence
of TSC2-218 K114A, suggesting that either TSC2-218 K114A does not bind to Rheb at all or
that it binds with no catalytic activity towards Rheb. This study emphasizes the need to
characterize the Rheb-TSC2-218 complex in order to get a detailed molecular picture of TSC2’s
catalytic mechanism as there is minimal information on the Rheb-TSC2 interaction due to the
lack of structural information on TSC2-218.

8

Figure 2. Schematic illustration of the TSC2-stimulated GTPase activity of Rheb. The
activity of Rheb is controlled by the nucleotide-bound state; GTP-bound Rheb (1XTS.pdb)
is active and GDP-bound Rheb (1XTQ.pdb) is inactive. The binding of TSC2 to active
Rheb-GTP (1XTS.pdb) 1 stimulates hydrolysis which diminishes the mTOR activity. The
structure of TSC2-218, currently unknown, was predicted using I-TASSER 2.
9

Figure 3. Regulation, or lack thereof, of TSC2-stimulated GTPase activity of
Rheb. (A) TSC2-218 WT functions as a GAP for Rheb by facilitating GTP
hydrolysis and inhibiting over-activity, represented by the longer dashed lines
indicating a stronger interaction. (B) Mutant TSC2-218 shows weaker or no
binding to Rheb (shorter dashed lines) leading to abnormal cell-signaling activity
or a loss of GAP activity. The structure of TSC2-218, currently unknown, was
predicted using I-TASSER 2.
10
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CHAPTER 2: EXPERIMENTAL

2.1 PROTEIN GROWTH, EXPRESSION AND PURIFICATION
2.1.1 CDC42 (WT AND T35A)
Cdc42 constructs were overexpressed as His6-tagged fusion protein from pET15b in the
Escherichia coli strain BL21 (DE3) in LB broth. A culture of LB containing 0.1 mg/mL
ampicillin was grown overnight at 37°C. This overnight culture was used to inoculate 1-2 liters
of fresh LB and was allowed to grow with shaking at 37°C until the OD600 reached 0.6-0.8. The
cells were induced with a final concentration of 0.2 mM IPTG (isopropyl-β-Dthioglactopyranoside) and allowed to express at 37°C for 4 hours. After expression, the cells
were harvested by centrifugation at 6,500 rpm for 20 minutes at 4°C. The pellet was resuspended
in 10 mM Tris (pH 8.0) and centrifuged again. The cell pellets were stored at -80°C.
To begin the purification process, each 1-liter pellet was thawed on ice and resuspended in lysis
buffer (25 mL Tris/NaCl binding (40 mM imidazole, 100 mM NaCl, 50 mM Tris pH 8.0, 10 mM
MgCl2), 25 mg lysozyme, Halt protease inhibitor cocktail to a final concentration of 0.5x,
DNAse, and 1 mM PMSF). Cells were lysed via sonication on ice (3 second pulse with 5 second
pause, 40 repetitions). The cell debris and the soluble fraction were separated by centrifugation at
18,000 rpm for 25 minutes at 4°C. The cell lysate as well as Tris/NaCl binding buffer and
Tris/NaCl elution buffer (250 mM imidazole, 100 mM NaCl, 50 mM Tris pH 8.0, 10 mM
MgCl2) were filtered before purification on AKTA FPLC using a 5-mL prepacked Ni2+ affinity
column (GE Healthcare HiTrap His Column). After the column was equilibrated with 5CV
Tris/NaCl binding buffer, the cell lysate was loaded over the column. A linear gradient was used
to increase the imidazole concentration for elution of the purified protein. The protein was either
11

dialyzed overnight at 4°C against the required buffer for the next experiment or lyophilized for
storage. For active Cdc42, Cdc42-His6 was nucleotide exchanged according to established
procedures 71. Briefly, Cdc42-His6 was incubated with 5 mM EDTA and 0.5 mM GTP analog for
3 hours at 4°C. Following incubation, EDTA and excess nucleotide were removed with an
equilibrated desalting column (GE Healthcare PD-10). 10 mM Mg2+ was replaced.
2.1.2 PBD46
PBD46, a peptide derivative of p21-activated kinase, was expressed as a GST fusion protein
from pGEX-2T in the E. coli strain BL21 (DE3) in LB broth to OD600 0.8-1.0 and induction with
0.5 mM IPTG for 5 hours at 37°C. GST-PBD46 was lysed as previously described for Cdc42,
except that the binding buffer was PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4) 72. A GSTrap FF 5 mL prepacked column (GE Healthcare) eluted with an
isocratic gradient of glutathione elution buffer (10 mM reduced glutathione, 20 mM Tris pH 8.0)
was used in purification.
As the GST tag is quite large (26 kDa), it was necessary to cleave off the tag. Thrombin
recognizes a specific amino acid sequence between PBD46 and the GST tag. PBD46 was
cleaved from the GST tag by incubation with thrombin (Sigma) for 5 hours at 4°C. After
incubation, Halt protease inhibitor was added to stop cleavage. The product was dialyzed in PBS
(pH 7.4) before loading onto a regenerated GST column as before to remove the GST tag.
2.1.3 RHEB
Residues 1-169 of Rheb were overexpressed as a His6-tagged fusion protein as described for
Cdc42 (page 11) using PBS Ni2+ binding (PBS pH 8.0, 50 mM MgCl2, and 25 mM imidazole)
and PBS Ni2+ elution (PBS pH 8.0, 50 mM MgCl2, and 400 mM imidazole) buffers.
12

For active Rheb, Rheb-His6 was nucleotide exchanged for one hour at room temperature.
2.1.4 TSC2-218 WT
As successful growth and overexpression of the GAP domain of TSC2 (TSC2-218) as a GST
fusion protein from pGEX-2T in the E. coli strain BL21 (DE3) in LB broth had not yet been
achieved in the lab, it was necessary to optimize these conditions. Existing stocks were used to
streak agar plates containing ampicillin and allowed to grow overnight at 37°C. Isolated
colonies were used to inoculate LB containing ampicillin. After expression (Figure 4), 1 mL
samples of each were pelleted by centrifugation. The supernatant was discarded and the pellet

Figure 4. GST-TSC2-218 Test Expression. After inoculated with overnight
culture, samples were expressed according to conditions in table. Pre-induced
sample (PI) taken at OD600 0.6. Condition C (OD600 0.8-1.0, 0.5 mM IPTG, room
temperature expression for 5-6 hours) yields the highest expression of GST-TSC2218 in the soluble fraction (demarked by black box).
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was then resuspended in 100 μL lysis buffer (PBS (pH 7.4), 10 mM MgCl2, and 0.1 mg/mL
lysozyme). The soluble and insoluble fractions were then separated; the suspension was
sonicated briefly and exposed to a freeze-thaw method of lysis. Centrifugation separated the
soluble (supernatant) and insoluble (pellet) fractions. The pellet was resuspended in 8M urea.
2X sample dye (100 mM Tris (pH 6.8), 4% SDS, 20% glycerol, 200 mM BME, and 0.2%
bromophenol blue) 72 was added to each sample before running on 15% SDS-PAGE. The
density of each band corresponding to the molecular weight of GST-tagged TSC2-218 (51 kDa)
represented a direct correlation to the amount of expression. Growth to OD600 0.8-1.0 and
induction with 0.5 mM IPTG at room temperature for 5-7 hours gave the highest yield of protein
in the soluble fraction.
GST-TSC2-218 was lysed as previously described for GST-PBD46. To determine the necessary
time required for cleavage, thrombin was added to the protein sample (1 unit thrombin per 150
μg protein) and incubated at 4°C. After each hour, a sample was removed and Halt protease
inhibitor added to stop cleavage. After 4 hours, each sample was run on SDS-PAGE (Figure 5).
TSC2-218 was cleaved from the GST tag by incubation with thrombin for 1-2 hours at 4°C as
described (page 12).
2.1.5 TSC2-218 K114A
Using Qiagen Plasmid Prep Kit, a plasmid of TSC2-218 was prepared from a 5-mL overnight
culture. The DNA concentration was determined via UV Vis at 260 nm. Once obtained, the
DNA was submitted with pGEX 3’ primer and pGEX 5’ primer to University of Arkansas DNA
Resource Center for sequencing. When the sequence of TSC2-218 WT was confirmed, primers
were designed to make the lysine to alanine point mutation at position 114. When designing the
primers for product TSC2-218 K114A, it was important that the primer sequence had minimal
14

Figure 5. SDS-PAGE of thrombin cleavage experiment. Lane 1 shows the
molecular weight marker. Lane 2 shows the GST-tagged TSC2-218 control.
Lanes 3-6 show the thrombin cleavage products after 1-4 hours, consecutively.
Thrombin cleavage is complete after 1 hour.
secondary structure, would not form a primer dimer, and that it had an acceptable G-C content
reflected by the melting point. The codon AAG translates to lysine and alanine is coded by
GCT, GCC, GCA, and GCG. The mutation of AAG to GCG was chosen as it requires the fewest
nucleotide changes. OligoAnalyzer (IDT) was used to monitor the various combinations of
primers for the optimal sequence. The forward and reverse primers used were:
Forward: CGACAAGGCGCGCCACCTGGG

Reverse: CCCAGGTGGCGCGCCTTGTCG

DNA calculator (Sigma) was used to analyze the primers for Tm, GC content, secondary
structure, and the likelihood of primer dimer formation; both primers show weak secondary
structure, no primer dimer, and have a Tm of 81.21 °C.
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A Quick Change Site Directed Mutagenesis Kit II (Stratagene) was used to form the point
mutation. The sample was prepped according to the kit; 5 μL 10X reaction buffer, 5-50 ng
dsDNA, 125 ng primer 1 (forward primer), 125 ng primer 2 (reverse primer), and1 μL dNTP mix
were combined and made to 50 μL with sterile water followed by the addition of 1 μL DNA
polymerase. The parameters on the PCR cycler are shown in Table 1. The amplified PCR
product was digested by addition of DpnI restriction enzyme and 1 hour incubation at 37°C. A
transformation into BL21 (DE3) competent cells immediately followed. This new construct was
labeled TSC2-218 K114A.
Segment

Cycle

Temperature (°C)

1

1

95°C

30 seconds

2

18

95°C

30 seconds

55°C

1 minute

68°C

2 min + (1 min/kilobase DNA)

Time

Set to hold at 4°C
Table 1. PCR settings for site-directed mutagenesis. The
kilobases of DNA for the protein and the primer totaled
5.638 kb. The time for the 68°C cycle of segment 2 was
set at 7.638 minutes.
Plasmid prep was again prepared and DNA submitted for sequencing. Sequencing results
showed that the point mutation was successful.
A test expression was repeated as described before (see page 13) to determine growth and
expression conditions for GST-TSC2-218 K114A as the mutation may have altered expression in
comparison to TSC2-218 WT. GST-TSC2-218 K114A was expressed at room temperature for 5
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hours after induction with 0.5 mM IPTG. Purification was identical to that for GST-TSC2-218
WT.
2.2 IN VITRO BINDING ASSAYS
Rheb-His6 was nucleotide exchanged according to previous protocols 71 (page 12) using
GMPPCP (Sigma). Equimolar Rheb-His6-GMPPCP and GST-TSC2-218 were incubated
together at 4°C for 12-16 hours. The sample was concentrated to 1 mL and purified using sizeexclusion chromatography. A HiPrep 16/60 Sephacryl S-100 HR column (GE Healthcare) was
used on AKTA FPLC. 10 microliters of each concentrated fraction was run on a 15% SDSPAGE. The in vitro binding assays were performed in triplicate.
2.3 CIRCULAR DICHROISM
Circular dichroism measurements were performed on a Jasco J-710 Spectropolarimeter. CD
spectra of purified protein samples were measured in the far-UV range (190-250 nm) in a 0.2
mm pathlength quartz spectrophotometer cell. Spectra were measured at 50 nm/min. The
concentration of protein solutions used for the CD measurements was 0.5 mg/mL in 10mM
phosphate buffer (pH 7.0). For difference spectra, the protein and ligand protein were combined
in a 1:1 ratio. Spectra Manager was used to collect the data in triplicate. 10 spectra were
obtained for each sample. From each spectrum, the spectrum of the buffer was subtracted using
Spectra Manager. For the difference spectra, the spectrum of the ligand protein was subtracted.
2.4 DIFFERENTIAL SCANNING CALORIMETRY
Differential scanning calorimetry measurements were performed using an N-DSC III Differential
Scanning Calorimeter (Calorimetry Sciences Corporation). Purified protein concentrations of 12 mg/mL were dialyzed extensively at 4°C in 10 mM phosphate buffer at pH 7.4. Spectra of the
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protein were recorded over a temperature range between 10 and 100°C at a heating rate of
2°C/min after degassing of the sample. A baseline obtained using the buffer was subtracted from
the protein spectra. Each protein sample was scanned in triplicate. CpCalc (Calorimetry Sciences
Corp) was used to obtain the melting curve and determine the Tm.
2.5 PROTEOLYTIC DIGESTION
Chymotrypsin (Sigma-Aldrich) and sodium dodecyl sulfate (J.T. Baker) were of molecular
biology or ultrapure grade. Limited proteolytic digestion experiments on TSC2-218 were carried
out at 25°C in 10 mM HEPES pH 8.0 in the presence of 10 mM CaCl2. Proteolytic digestions
were performed in triplicate at an enzyme (chymotrypsin) to substrate (TSC2-218) molar ratio of
1:15. The protease activity was stopped after desired time intervals by the addition 1% SDS and
the pH adjusted to 2.0 by the addition of 1 μL 12.1 M hydrochloric acid (EMD) and heating for 5
minutes at 100°C to abolish all enzyme activity 73, 74. The degree of proteolytic cleavage was
measured from the intensity of the 24 kDa band on a 15% SDS−PAGE gel corresponding to the
untreated protein (TSC2-218) using UN-SCAN-IT gel 6.1 software. The intensity of the
protease-untreated 24 kDa band (TSC2-218) was used as the control for 100% protection against
proteolytic digestion. Chymotrypsin control concentration was verified by UV-absorbance at 280
nm.
2.6 GTP HYDROLYSIS ASSAY
GTP hydrolysis assays were carried out to characterize differences of hydrolytic activity of WT
vs mutant proteins for the Cdc42-PBD46 and Rheb-TSC2-218 interactions.
All chemicals were ultrapure or of molecular biology grade and all chemical solutions were
prepared fresh before each assay. The Ras protein (Rheb or Cdc42) was nucleotide exchanged
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using GTP by incubating the protein with freshly prepared 0.5 mM GTP (Sigma) and 5 mM
EDTA (EMD) to remove bound Mg2+. EDTA and any excess nucleotide were removed by
passing through a PD-10 desalting column (GE Healthcare) and then 10 mM MgCl2 was added to
the protein solution to incorporate Mg2+ back on the protein. The Ras protein bound to GTP was
immediately passed over a PD-10 column again to remove any endogenously hydrolyzed Pi
released prior to the GTP hydrolysis assay.
Time-dependent GTP hydrolysis was performed with TSC2-218 using a 1:2.5 molar ratio of
GTP-bound Rheb (10 μM) to TSC2-218 (25 μM). To initiate hydrolysis, each protein mixture
was mixed with 2 mM GTP in 10 mM HEPES pH 8.0 (J.T. Baker) to a final volume of 1 mL and
incubated at 25°C. For measuring GTP hydrolysis as a function of time, the hydrolysis was
stopped after desired time intervals (0, 10, 20, 30, 45, 60, and 90 min) via protein denaturation
by the addition of 6% SDS (J.T. Baker). For the GTP hydrolysis assay as a function of TSC2218 concentration, 10 μM Rheb was incubated with TSC2-218 at varying concentrations for 30
minutes, and the hydrolysis measured at each concentration of TSC2-218. To monitor GTP
hydrolysis, 6% ascorbic acid and 1% ammonium molybdate (Sigma) were added to the protein
mixture, followed by 3-7 minute incubation at room temperature. Sodium citrate (Sigma),
sodium metaarsenite (J.T. Baker), and acetic acid (EMD) (1% each) were added to the denatured
protein mixture and incubated for an additional 20 minutes and then assayed for any color
changes at 850 nm according to established methods (Figure 6) 75, 76. To calibrate the assay,
GTP was added after protein denaturation and the absorbance of this sample was read and
subtracted from the desired sample absorbance at each time point. Using K2HPO4 as a phosphate
source, 0-75 nM phosphate was assayed in triplicate to generate a linear standard curve used to
calculate the amount of Pi released. The average change in Pi released as a function of time was
19
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Figure 6. Pi monitoring by molybdate. (A) Cdc42
(WT), as well as Cdc42 (T35A), hydrolyzes GTP,
evident by formation of the blue colored complex. (B)
The interaction of PBD46 inactivates Cdc42 (WT) by
preventing hydrolysis; no colored complex forms as no
inorganic phosphate is released. Although molybdate
and ascorbic acid were added, without phosphate
present as a result of hydrolysis, no colored complex
forms. (C) The weaker interaction of PBD46 with
Cdc42 (T35A) partially restores hydrolysis. The lower
yield of inorganic phosphate results in less colored
complex formation, evident in the lighter blue color.
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determined by averaging the values from triplicate experiments and calculating the difference for
each time point from the time-zero value. To measure GTP hydrolysis of Cdc42 (WT and
T35A), the Cdc42 was assayed in the absence and presence of PBD46 as a function of time and
as a function of PBD46 concentration as described for the Rheb-TSC2-218 interaction.
2.7 2D-HSQC NMR
2.7.1 SAMPLE PREPARATION
To initiate growth, an overnight culture of either Rheb or TSC2-218 was grown in LB. The cells
were pelleted via centrifugation and washed twice with NMR buffer (10 mM NaH2PO4, 5 mM
MgCl2, and 100 mM NaCl). The cells were resuspended in unlabeled M9 minimal media (47.8
mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 18.7 mM NH4Cl, 2 mM MgSO4, 0.1 mM CaCl2,
and 0.4% glucose supplemented with a vitamin solution (.325 mg each of pantothenoic acid,
choline chloride, folic acid, myo-inositol, nicotinamide, pyridoxyal hydrochloride, and
riboflavin) and 25 mg/L thiamine) 72 and allowed to grow overnight. The overnight culture was
used to inoculate fresh M9 media and monitored for the highest expression yield. 15N Rheb and
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N TSC2-218 were overexpressed in 15NH4Cl enriched minimal medium according to the

demarcation in Figures 7 and 8, respectively, by induction with IPTG at room temperature.
Purification was the same as for unlabeled samples (pages 12-14).
2.7.2 SPECTRA ACQUISITION
2D NMR experiments were performed on a Bruker Avance-500 MHz or 700 MHz NMR
spectrometer at 25°C using TopSpin NMR. 500 μL of 0.1-0.5 mM labeled was dialyzed (TubeO-DIALYZER from G Biosciences) in NMR buffer (10 mM NaH2PO4, 5 mM MgCl2, 100 mM
NaCl, pH 5.5) and 15% D2O was added. The spectra were processed using XWINNMR and
Sparky software.
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Figure 7. 15N Rheb Test Expression. 15N-Rheb Test Expression. Samples were
expressed according to conditions in table. All samples expressed for 16 hours.
Condition F (OD600 0.4, 1.0 mM IPTG, room temperature expression) yields the
highest expression of 15N-Rheb (demarked by black outline).

Figure 8. 15N-GST-TSC2-218 WT Test Expression. Samples were expressed
according to conditions in table. All samples expressed for 16 hours. Condition C
(OD600 0.7, 0.5 mM IPTG, room temperature expression) yields the highest expression
of 15N-GST-TSC2-218 WT (demarked by black outline).
23
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CHAPTER 3: RESULTS AND DISCUSSION

3.1 INTRINSIC GTP HYDROLYSIS IS OBSERVED FOR A SWITCH I MUTANT OF CDC42 IN THE
PRESENCE OF A SPECIFIC GTPASE INHIBITOR PEPTIDE DERIVATIVE
Studies on the conformational flexibility of a Cdc42 mutant show that with decreased
flexibility, Cdc42 T35A binds to effector proteins less 3. As previously described, PBD46
prevents GTP hydrolysis of Cdc42 38. To compare the effects of the hydrolysis of Cdc42 T35A
to Cdc42 WT, we examined the GTP hydrolysis of Cdc42 (WT and T35A) both alone and in the
presence of PBD46. Shown in Figure 9, a linear decrease in Pi released was seen for both
Cdc42 WT and T35A, although variation
is seen in the slopes. At a concentration of
10 μM PBD46, where the [Cdc42
WT]:[PBD46] = 1:1, total inhibition of
GTP hydrolysis is seen. The saturation
point for Cdc42 T35A was seen at
approximately 16 μM PBD46, 1:1.6
[Cdc42 T35A]: [PBD46]. Further addition
Figure 9. PBD46 concentration dependent GTP
Hydrolysis. 10 μM Cdc42 (WT and T35A)
(black and red, respectively) was assayed in the
presence of increasing concentrations of PBD46.
Saturation of Cdc42 WT occurs at 10 μM
PBD46 ([Cdc42 WT]:[PBD46] = 1:1), at which
point GTP hydrolysis is completely inhibited.
Saturation of Cdc42 T35A occurs at 16 μM
PBD46 ([Cdc42 WT]:[PBD46] = 1:1.6). T35A
hydrolysis is only inhibited ~70% compared to
100% inhibition of WT hydrolysis at PBD46
saturation.
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of PDB46 does not have an effect on the
GTP hydrolysis of activity of Cdc42 T35A
above this saturation point.
A time-dependent GTP hydrolysis
assay of 10 μM Cdc42 (WT and T35A) in
the absence and presence of 30 μM PBD46

was used to calculate and compare GTP hydrolysis rates according to the following equation:

(

)

where Pi(t) is the amount of inorganic phosphate released as a function of time (t), Pi(max) is the
maximum amount of inorganic phosphate released, and kobs is the apparent first-order rate
constant (Figure 10). Consistent with
previous results 38, Cdc42 WT showed a
high rate of GTP hydrolysis (95.5 ± 4.8
nmol Pi released) after 90 minutes in
comparison to Cdc42 WT in the presence
of PBD46 (0 nmol Pi released). As there
was no hydrolysis, this supports previous
observations that PBD46 inhibits
hydrolysis of Cdc42 WT. Examination of the T35A mutation in the absence of PBD46 showed
similar results to WT after 90 minutes (92.6 ±
Figure 10. Time-dependent Cdc42 GTP
Hydrolysis Assay. 10 μM Cdc42 (WT and
T35A) was assayed in the absence and
presence
of
30μM
PBD46
(1:3
[Cdc42]:[PBD46]. Cdc42 WT and T35A
show comparable GTP hydrolysis. In the
presence of PBD46, intrinsic GTP hydrolysis
is completely inhibited for Cdc42 WT. Cdc42
T35A exhibits partial restoration of
hydrolysis in the presence of PBD46.

5.4 nmol Pi released), translating to similar
first-order rate constants (0.0868 ± 0.0044
min-1 and 0.0839 ± 0.0086 min-1,
respectively). Upon addition of PBD46,
hydrolysis was partially restored for Cdc42
T35A (32.5 ± 4.3 nmol Pi released) with a

slower first-order rate constant of 0.0459 ± 0.0047 min-1. These results are summarized in Table
2.
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Pi max (nmol)

Kobs (min-1)

Cdc42 WT

95.5 ± 4.8

0.0868 ± 0.0044

Cdc42 WT + PBD46

N/A

Cdc42 T35A

92.6 ± 5.4

0.0839 ± 0.0086

Cdc42 T35A + PBD46

32.5 ± 4.3

0.0459 ± 0.0047

Table 2. Pi max and Kobs for Cdc42 (WT and T35A) in
the absence and presence of PBD46 determined via a
time-dependent GTP hydrolysis
Although the T35A mutation does not appear to affect the intrinsic GTP hydrolysis rate
for Cdc42 in comparison to WT, the partial restoration of GTP hydrolytic activity in the presence
of PBD46 observed for the T35A mutation can be attributed to the weaker binding affinity
between the GTPase and its effector. This exhibits a link between the conformational flexibility
and effector binding; the more rigid switch I region of Cdc42 T35A binds more weakly to
PBD46, partially restoring GTP hydrolysis.
Our results show that, as a result of this weaker binding, some of the intrinsic GTP
hydrolysis is restored in the presence of the GTPase inhibitor PBD46. The different slopes of the
linear decrease in Pi released at low PBD46 concentrations for Cdc42 WT and Cdc42 T35A
(Figure 9) are evidence that Kd for PBD46 binding to Cdc42 T35A is lower than that observed
for WT, which is approximately 20 nM 38. The difference in Kobs, taken together with the
difference in Pi max observed for Cdc42 T35A in the presence of PBD46 compared to Cdc42 WT
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Figure 11. Proposed Cdc42 Kinetic Scheme. (A) Upon Cdc42 WT
binding to PBD46, complete inhibition of GTP hydrolysis occurs as a
result of tight binding. (B) Upon saturation of PBD46, Cdc42 T35A
shows a reduced amount of hydrolysis compared to that in the absence of
PBD46, but complete inhibition is not seen, implying that there may be
two interconverting conformational states with different binding affinities
to PBD46.
in the presence of PBD46, is telling of two conformations of Cdc42 T35A that have slow
interconversion rates (Figure 11B), which is an idea that has been hypothesized for Ras T35A 33.
Although both conformations of Cdc42 T35A are capable of hydrolyzing GTP, one form has
weakened or diminished binding to PBD46 which prevents PBD46 from completely inhibiting
hydrolysis. The first order rate constants are the same for Cdc42 WT and T35A in the absence
of PBD46, seen in TABLE 2, as a result of kinetics studies (Figure 10); this supports the
proposed model of interconverting T35A conformational states that are both capable of
exhibiting intrinsic GTP hydrolysis.
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3.2 CHARACTERIZATION OF THE INTERACTION BETWEEN RHEB AND TRUNCATED TUBEROUS
SCLEROSIS COMPLEX 2 CONSTRUCTS
The GAP domain of TSC2 is highly conserved across many species ranging from yeast to
human 77, 78. This GAP domain binds to Rheb in vitro and in vivo. Mutations in the GAP
domain have been described as leading to the onset of the diseased state of tuberous sclerosis,
due to the function of the GAP domain to increase intrinsic GTP hydrolysis activity of Rheb 46,
53-55, 68-70

(Figure 2). Neither the underlying mechanism by which TSC2 catalyzes GTP

hydrolysis nor the details of the protein interaction are yet completely understood.
As a control, we confirmed binding between Rheb and TSC2-218 through an in vitro binding
assay of GST-tagged
TSC2-218 with Rheb. The
concept lies in using the
affinity tags to identify
protein interactions. If any
untagged protein appeared
in the elution, it would show
that the proteins were in
complex. The specific GSTtag was exploited. One of
multiple assays showed
complex formation
(FIGURE 12). In the

Figure 12. In vitro binding pull-down assay. Lanes 1 and 2
show the GST-TSC2-218 WT and Rheb controls, respectively.
Lane 3 shows the molecular weight marker. Lane 4 shows the
GST-TSC2-218-Rheb mixture before incubation. Lanes 5-8
show subsequent washes. Lanes 9 and 10 show subsequent
elutions. In the final wash before elution (lane 8), there is little
to no protein shown. In the first elution (lane 9), bands
representative of both Rheb and GST-TSC2-218 appear.
Because glutathione beads were used, the only way for Rheb
to appear in the elution is if it were bound to GST-TSC2-218,
which bound to the beads. This confirms complex formation.

elution peak, a band for
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GST-TSC2-218 (51 kDa) and a band for Rheb (21 kDa) appear. Rheb did not appear in the last
wash before the elution; this leads to the conclusion that the only way Rheb could appear in the
elution is if it was bound to GST-TSC2-218. Rheb alone does not bind to the glutathione
sepharose. Size-exclusion chromatography, which separates protein systems based on size, was
next applied. The large complex (72 kDa) would elute before the unbound GST-TSC2-218 and
Rheb (51 kDa and 21 kDa, respectively) (Figure 13A).
It was necessary to use GST-tagged TSC2-218 in order to separate the complex from both
unbound samples due to the resolution limits of the column. When the complex peak was run on
SDS-PAGE, one band does not appear at the complex molecular weight (72 kDa), but rather a
band appears representing each individual protein of the complex; the composition of the sample
dye used for SDS-PAGE breaks the complex into its separate components. The approximately

Figure 13. In vitro binding assay of equimolar GST-TSC2-218 WT and Rheb. (A) FPLC
size exclusion chromatogram showing complex (peak 2), unbound GST-TSC2-218 (peak 3),
and unbound Rheb (peak 4). (B) SDS-PAGE results following size exclusion chromatography.
The first three lanes represent the control of GST-TSC2-218 WT and Rheb, respectively,
followed by the molecular weight marker. Lane 3 contains the molecular weight marker. Lanes
labeled 1-4 represent peaks 1-4 from the chromatogram showing the absence of protein,
complex, unbound GST-TSC2-218, and unbound Rheb, respectively.
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equal intensities of unbound GST-TSC2-218 and Rheb suggest that the binding is 1:1 as the
assay was done with equimolar starting concentrations of the proteins (Figure 13B).
Once our controls had been established, a tuberous sclerosis associated single point
mutation was designed. The K114A (K138A in full-length TSC2) substitution has been observed
in tuberous sclerosis patients and so it was of interest to investigate what effects this point
mutation had on the TSC2-218 – Rheb interaction and GAP function of TSC2-218 79. Other
point mutations at this residue eliminated GAP activity 45. Once expression and purification of
TSC2-218 K114A were achieved, an in vitro binding assay with Rheb was done. The proteins
were loaded onto a size-exclusion column as done for WT (page 14) (Figure 14). An elution
peak for unbound GST-TSC2-218 WT as well as for Rheb was seen. However, unlike with
wild-type TSC2-218, no complex formation was observed with TSC2-218 K114A (FIGURE

Figure 14. In vitro binding assay of equimolar GST-TSC2-218 K114A and Rheb. (A) FPLC
size exclusion (S100) chromatogram showing unbound GST-TSC2-218 K114A (peak 1),
unbound Rheb (peak 2), and lack of complex formation. (B) SDS-PAGE results following size
exclusion chromatography. The first two lanes represent the control of GST-TSC2-218 K114A
and Rheb, respectively, followed by the molecular weight marker. Lanes labeled 1 and 2
correspond to peaks 1 and 2 from the chromatogram showing unbound GST-TSC2-218 K114A
and unbound Rheb, respectively. There is no complex formation.
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14A), evidenced by the lack of peak at 45 mL elution. This preliminarily shows that TSC2-218
K114A does not interact with Rheb and, therefore, cannot act as a GAP to regulate cell signaling.
Circular dichroism (CD) and differential scanning calorimetry (DSC) were used to
characterize the TSC2-218 mutant in comparison to the wild-type. TSC2-218 WT shows slight
secondary structure, but a change in secondary structure is seen in TSC2-218 K114A (Figure
15A). The difference in secondary structure of the K114A mutant parallels a 5°C decrease in
thermal stability as compared to
WT (TSC2-218 unfolds at 60.6 ±
0.32°C and TSC2-218 K114A at
55.5 ± 0.42°C) (Figure 16). A CD
comparison of TSC2-218 WT in
the absence and presence of Rheb
shows that upon binding to Rheb,
Figure 16. Differential Scanning Calorimetry. TSC2218 WT exhibits a Tm of 60.6 ± 0.32°C. A 5°C decrease
in thermal stability of TSC2-218 K114A is seen with a
Tm of 55.5 ± 0.42°C.

there is a slight change in the
secondary structural features of
TSC2-218 WT (Figure 15B),

possibly supporting some form of an induced-fit model of binding. Conversely, there is no
change evident in TSC2-218 K114A in the presence or absence of Rheb (Figure 15C). As
changes in secondary structure were induced by the single-point mutation, a limited
chymotrypsin digestion assay was used to monitor for any differences in cleavage patterns when
exposed to chymotrypsin at an enzyme to protein ratio of 1:15. As Figure 17 shows, different
cleavage patterns were seen for WT and K114A, resulting in cleavage of 14% of TSC2-218 WT
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Figure 15. Circular dichroism. (A) CD spectra of
TSC2-218 (WT and K114A). The K114A mutation
appears to cause a decrease in secondary structure
compared to WT. (B) CD spectra of TSC2-218 WT
and difference spectra of TSC2-218 WT in the presence
of Rheb. A slight change in the secondary structure is
seen when bound to Rheb compared to unbound. (C)
CD spectra of TSC2-218 K114A and difference spectra
of TSC2-218 K114A in the presence of Rheb. No
change is seen in the absence and presence of Rheb,
implying that TSC2-218 K114A does not interact with
Rheb.

and only 9.8% cleavage of TSC2-218 K114A after 180 minutes exposure to chymotrypsin
activity. As chymotrypsin cleaves at the carboxylic side of aromatic amino acids, no change
would be expected in cleavage patterns unless a conformational change was induced; some
conformational change imparted by the K114A mutation leads to slight protection from
enzymatic cleavage.
Rheb differs from other Ras proteins in that it has an intrinsically low rate of GTP hydrolysis and
requires regulation to prevent overactivity; the activity of TSC2-218 WT as a GAP functions to
regulate this activity by facilitating GTP hydrolysis 55. In order to compare the TSC2-stimulated
GAP activity of Rheb between TSC2218 WT and K114A, we examined the
GTP hydrolysis of Rheb alone and in the
presence of TSC2-218 (Figure 18).
Consistent with previous results 45, Rheb
showed essentially no intrinsic GTP
hydrolysis (6.8997 ± 2.4703 nmol Pi
released). After 120 minutes, Rheb in the
presence of TSC2-218 WT released
61.7143 ± 1.3788 nmol Pi with a T½ of
23.1 minutes compared to 6.8997 ±
2.4703 nmol Pi released in the absence of
TSC2-218 WT (Table 3). In the
presence of TSC2-218 K114A, no

Figure 18.
Time-dependent Rheb GTP
Hydrolysis Assay. 10 μM Rheb was assayed in the
absence and presence of 30μM TSC2-218 (WT
and K114A) (1:3 [Rheb]:[TSC2-218]). In the
absence of TSC2-218, Rheb shows very little
intrinsic hydrolysis over time, displaying its
characteristic “locked” GTP-bound state. Upon
addition of TSC2-218 WT, GTP hydrolysis is
facilitated. In the presence of TSC2-218 K114A,
no increase in hydrolysis is seen in comparison to
Rheb alone.
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Figure 17. Limited Chymotrypsin Digestion. Representative SDS-PAGE of the products
of digestion for TSC2-218 WT (A) and K114A (B). The gels show the chymotrypsin (•)
and TSC2-218 (*) controls, the molecular weight marker, and the digestion products as a
function of exposure time. (C) Graphical depiction of the percent of uncleaved TSC2-218
WT (black) and TSC2-218 K114A (red).

Sample

T½

k

RhebA

1029 min

6.7 x 10-4 min-1

Rheb + TSC2-218 WTA

21.7 min

3.1 x 10-2 min-1

Rheb + TSC2-218 WTB

23.1 min

3.0 x 10-2 ± 0.003 min-1

Table 3. T½ and rate constant for Rheb GTP Hydrolysis.
Comparable values were obtained via the molybdate method
used here (B) and NMR-based assay used by Marshall, et al (A)

increase in GTP hydrolysis was evident (7.4167 ± 0.8124 nmol Pi released).
A concentration-dependent GTP
hydrolysis assay of 10 μM Rheb in the
presence of increasing concentrations of
TSC2-218 (WT and K114A) was used
to compare GTP hydrolysis according to
the following equation:
[
[

]
]

where Pi is the amount of inorganic
phosphate released, K is the apparent
association constant, and n is the Hill
coefficient, which gives an idea of
cooperativity and may give information on
the number of ligand binding sites

Figure 19. TSC2-218-concentration dependent
GTP Hydrolysis Assay. 10 μM Rheb was
assayed for 30 minutes in the presence of
increasing concentrations of TSC2-218 (WT and
K114A). The binding constant and Hill
coefficient were calculated from the Rheb –
TSC2-218 WT curve.
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(Figure 19). The TSC2-218 WT – Rheb interaction released a maximal 44.4 ± 1.2 nmol Pi with a
binding constant, K, of 5.4 ± 0.11 μM and a Hill coefficient of 5.3 ± 0.4. The positive Hill
coefficient (5.3 ± 0.4) calculated from the sigmoidal kinetics studies (Figure 19) implies that
there may be more than one binding domain for TSC2-218-Rheb binding.
2D HSQC NMR spectroscopy was used to determine if chemical shift changes occurred in
15

N-labeled Rheb in the absence and presence of TSC2-218. A 2D HSQC overlay of 15N Rheb in

the absence and presence of natural abundance TSC2-218 WT (Figure 20A) or TSC2-218
K114A (Figure 20B) did not show any discernible chemical shift changes as also shown by
Marshall, et al.
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Figure 20. 15N Rheb 2D HSQC NMR Spectroscopy. 15N Rheb was run in the absence (red)
and presence of (A) TSC2-218 WT (black) and (B) TSC2-218 K114A (blue). No chemical
shift changes were evident in the presence of either TSC2-218 construct, although we know
that binding occurs between Rheb and TSC2-218 WT. Spectra were obtained on Bruker
Avance 700 MHz NMR using TopSpin and the data analyzed using Sparky software.
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As there is no structural information to date on TSC2, it is of upmost importance to
determine the structure to be able to fully characterize the TSC2-Rheb interaction. Tremendous
efforts have also been unsuccessful in many other labs to obtain a 2D HSQC of TSC2-218 87,
perhaps due to the protein’s tendency to aggregate at high concentrations needed for NMR.
Protein prediction software predicted the structure of TSC2-218 to consist of ~25% α helix,
~25% β sheet, and ~50% random coil (Figure 22) 2. Our attempts at obtaining a spectrum proved
to be quite difficult. At lower TSC2-218 concentrations used for CD, DSC, etc., there were no
problems with aggregation; at higher concentrations necessary for NMR, protein showed
physical signs of aggregation in the NMR tubes, resulting in poor peak dispersion as evidenced
in the spectra (Figure 21). Efforts to obtain spectra at 15°C in the presence of 10% glucose did
not improve and reduce aggregation (not shown). We will continue to work with this protein and
attempt change some aspects of the sample preparation in hopes to obtain an acceptable
spectrum.

Figure 21. 15N TSC2-218 WT 2D HSQC NMR Spectroscopy. 15N
TSC2-218 WT was run in the absence (blue) and presence (red) of
Rheb. In both spectra, peaks characteristic of aggregation of
evident. Spectra were obtained on Bruker Avance 700 MHz NMR
using TopSpin and the data analyzed using Sparky Software.
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4

CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS

4.1 INTRINSIC GTP HYDROLYSIS IS OBSERVED FOR A SWITCH I MUTANT OF CDC42 IN THE
PRESENCE OF A SPECIFIC GTPASE INHIBITOR PEPTIDE DERIVATIVE
Mutation of an invariant threonine residue in Cdc42, which causes a decrease in flexibility,
does not affect the intrinsic GTP hydrolysis rate of Cdc42, but does alter the binding to an
effector protein, PBD46. The disturbed binding leads to Cdc42 T35A GTP hydrolysis even in the
presence of the GTPase inhibitor. As a result of our studies, we proposed the presence of
multiple interconverting conformational states of Cdc42 T35A, one of which has a decreased
affinity for PBD46.
Further characterization studies outlining the binding interface between PBD46 and Cdc42
T35A could give insight into the molecular details that lead to the less dynamic switch I region
and highlight specific residues that contribute to weaker binding as well and make available a
target for the design of ways to regulate protein interactions and, therefore, abnormal cell
signaling. Fluorescence spectroscopy studies could be employed to study these two
interconverting conformational states of Cdc42 T35A by calculating the KD and NMR
spectroscopy could be used to outline the Cdc42 T35A – PBD46 binding interface. If there was a
way to restrict flexibility by binding small molecules, it may be possible to control oncogenic
protein-protein interactions. Shown here, a decrease in flexibility in Cdc42 T35A leads to
altered binding with an effector protein (PBD46). Since the idea of using small molecules to
target oncogenic proteins was first conceptualized by Tavares, et al 80, recent studies have
targeted Ras proteins with small molecules through the use of structure based drug design
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(SBDD) 81. More needs to be known on how this would affect the overall structure of the protein
and if it would cause any unwanted/unexpected functional changes.
Unlike Cdc42 T35A which exhibits a slow exchange rate as a result of decreased
flexibility, Cdc42 F28L is characterized by an increased exchange rate between GTP and GDP as
a result of an increase in flexibility 85. Ongoing studies using GTP may provide insight as to
how the F28L mutation alters the affinity for the nucleotide. The structure-function relationship
of this mutant needs to be further studied. Our lab is able to express and purify the mutant.
Plans are underway to use DSC to compare the thermal stability of both the GTP- and GDPbound forms of Cdc42 T35A with WT. Any differences might further explain why the fastcycling occurs. GTP hydrolysis assays can also be employed to study the modification on
hydrolysis in the absence and presence of PBD46. Pending the outcome of these results, NMR
can be used to outline the binding interface and identify the changes in the structure-function
relationship of Cdc42 T35A in comparison to Cdc42 WT.
4.2 CHARACTERIZATION OF THE INTERACTION BETWEEN RHEB AND TRUNCATED TUBEROUS
SCLEROSIS COMPLEX 2 CONSTRUCTS
Rheb differs from other Ras proteins in that it has an intrinsically low rate of GTP
hydrolysis and requires regulation to prevent overactivity; the activity of TSC2-218 WT as a
GAP functions to regulate this activity, as shown in Figure 18. There is no structural
information to date on TSC2 though protein prediction software predicted the structure of TSC2218 to consist of ~25% α helix, ~25% β sheet, and ~50% random coil (Figure 22) 2. It is of
upmost importance to determine the structure to be able to fully characterize the TSC2-Rheb
interaction. Although efforts in our lab as well as in many other labs to obtain a 2D HSQC of
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TSC2-218 has proven to be quite difficult 87, we will continue to work
with this protein and attempt to change some aspects of the sample
preparation in hopes to obtain an acceptable spectrum. The
TSC2 binding domain of TSC1 has recently been gifted by
Wenqing Xu (University of Washington). Based on TSC1’s
stabilizing role when in complex in TSC2 63, 64, pending successful
transformation, growth and expression, TSC1 may prove to be
necessary in complex with TSC2-218 in order to determine the
structure of TSC2-218 WT. If this proves to be unmanageable, we
may need to turn our efforts to X-ray crystallography in order to
get a structure of TSC2-218 for comparison with and without

Figure
22.
Structure
prediction of TSC2-218
WT using I-TASSER.

Rheb.
The disease-causing mutant TSC2-218 K114A was shown here to not function as a GAP
for Rheb (Figure 18), allowing for Rheb to remain in a “locked” GTP-bound active state. The
biophysical studies presented here lead to the conclusion that the single-point mutation causes
secondary structure changes that result in an altered interaction with Rheb. Is the loss of binding
to Rheb a result of a change in conformation that prevents access to the binding site or are the
molecular details of the binding site altered? As we begin to understand the chemical and
biological details of this protein interaction, we now have a platform on which to expand the
studies of structure-function relationships of these proteins, with particular interest to mutations
that alter structure and function.
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Another mutant, the Asn119Lys119 mutant of TSC2-218 (equivalent to Asn1643Lys1643
in full-length TSC2), is a disease-causing mutation of what is thought to be the catalytic
asparagine residue required for the asparagine thumb mechanism by which TSC2 increases
GTPase activity of Rheb 45, 88. The mutation removes an amide group and replaces it with a
basic amine. Previous studies of other disease-associated point mutations of the proposed
catalytic asparagine thumb have eliminated the GAP activity of TSC2 45. Pending successful
mutation design and expression, we plan to further study and characterize TSC2-Rheb binding
by studying the N119K mutation in the same manner as the K114A mutation.
In TSC2, exploration of another disease-causing mutation D1690 (D74 in TSC2-218),
which lies in a region adjacent to the binding domain, did not inhibit GAP activity towards Rheb
in vitro 45. Unlike with many other mutants studied, it is not clear as to why this mutation is
disease-causing in vivo. Is it possibly that this residue is, in part, responsible stabilizing Rheb in
complex with TSC2? Further studies on this residue and its importance to TSC2 might reveal a
new mechanism for oncogenic nature that has not been identified.
A mutant of Rheb in which the cysteine responsible for farnesylation is mutated to serine,
thereby removing the free sulfur group, Rheb (C181S), shows a lower GTP level but still
interacts with TSC246, 62. Recent work has hypothesized that farnesylation is important for Rheb
stimulation by GEF and that the GEF is responsible for the decreased ratio of GTP:GDP binding
50

. It would be beneficial to identify a Rheb GEF in order to develop ways to block or alter the

interaction; without Rheb GEFs, Rheb may be more susceptible to be in the GDP-bound inactive
state.
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Much still remains unknown about the Rheb/TSC2 interaction, especially directed at TSC2.
Although multiple studies have been done, there is still no sure answer as to whether TSC1 plays
a role in TSC2-stimulated GTPase activity of Rheb. TSC1 has been shown to be required by
several groups 53, 55, 62 while other groups have shown that it is not required 46, 50. What function
does the TSC1/TSC2 heterodimer display that is different from either TSC1 or TSC2 alone? It is
possible that TSC1 is only required for stabilization of TSC2 63, but it may play a more
significant role than has been identified. Very recently, Tre2-Bub2-Cdc16 1 domain family,
member 7 (TBC1D7) has been identified as a third core subunit of the TSC1/TSC2 complex and
preliminary studies have shown that the complex formed (TSC-TBC) functions as a Rheb-GAP
by sensing cellular growth conditions 89. As new information, much more in depth research
needs to be done to outline and understand completely the interaction and its mechanism.
4.3 CONCLUSIONS
Ras-like GTPases are of biological importance for their GTP hydrolysis mechanism; they
are signal transduction proteins responsible for sending signals to the cell nucleus. Their role in
cell signaling cascades will always be the target for studies as long as improper interactions
occur in vivo that play a role in abnormal cell signaling activities.
The studies presented here are centered on understanding the relationship that lies between
structure and function in Ras-related proteins. Most oncogenic Ras proteins are locked in a
continuously active state, often facilitated by mutations that alter the intrinsic GTP-hydrolytic
activity 90. Structural changes imparted by something as small as a single point mutation can
drastically alter the function of the protein. The threonine to alanine mutation in Cdc42 led to
weaker binding and consequently partially restored the hydrolytic activity of Cdc42 in the
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Cdc42-PBD46 interaction. As preliminarily seen in the Rheb-TSC2 interaction, the lysine to
alanine point mutation (K114A) inhibited the interaction, possibly leading to overactivity of
Rheb and prolonged cell signaling. Further exploration of these mutations, as well as the
asparagine to lysine point mutation (N119K) and aspartic acid to alanine mutation (D74A) in
TSC2-218 and the phenylalanine to leucine mutation (F28L) in Cdc42, are needed for
characterization of the effects imparted by these mutations on the structure and function of these
proteins and their interactions as part of a regulatory process.
A better understanding of the significance of changes on structure in Ras proteins is
needed; it is necessary to provide a direct link between molecular aspects of interactions between
proteins and begin to identify ways to regulate or alter aberrant cell signaling. Hopefully, this
work can provide a foundation to promote the discovery of molecular features of Ras proteins
that can aid in the modulation of the interactions that lead to diseased-states. In order to exploit
any of these proteins as potential drug targets, much more needs to be understood concerning the
protein-protein interactions, with a special interest in those interactions affected by mutations.
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